SEO URLwww.firestrike.ai/deals/cidara-therapeutics-merck-acquisition-2026-1
acquisitionAnnounced · Jan 7, 2026BiotechnologySource · CredibleArticle · Factual
Merck acquires Cidara Therapeutics
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$9.2B
Target
Cidara Therapeutics
NASDAQ: CDTX · San Diego, California
Acquirer
Merck
Full Acquisition
Status
Pending
Merck agreed to acquire Cidara Therapeutics. Reported deal value: $9.2B. Status: Pending. Sector: Biotechnology. Target headquarters context: San Diego, California, United States.
This page summarizes publicly available information about the transaction as of 2026-01-07. Figures and status may change as filings and press coverage update.
Search jobs 07-Jan-2026 Merck to Complete Acquisition of Cidara Therapeutics in $9.2 Billion Deal Merck is set to finalise its purchase of Cidara Therapeutics , a move that adds a promising late-stage antiviral to its portfolio and strengthens its infectious disease pipeline
Deal timeline
Announced
Jan 7, 2026 · pharmiweb.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biotechnology with a reported deal value of $9.2B. Figures and status may change as sources update.
Sources: pharmiweb.com · Primary article · FireStrike proprietary index